SHELTON, Conn., Feb. 22, 2016 /PRNewswire/ -- NanoViricides, Inc.
(NYSE MKT: NNVC (the "Company") announced today that information on
its novel, proprietary anti-virus platform technology has been
published in the book "Handbook of Clinical Nanomedicine, Vol.
1. Nanoparticles, Imaging, Therapy, and Clinical
Applications", a CRC Press publication. The chapter entitled
"Nanoviricides: Targeted Anti-Viral Nanomaterials" provides an
in-depth presentation of the NanoViricides platform technology,
evidence for how nanoviricides® are believed to act plus dramatic
results of nanoviricides specifically targeting certain viral
diseases, such as Influenza.
This chapter introduces the novel NanoViricides nanotechnology
that possesses potent antiviral efficacy by targeting the
mechanisms by which viruses attach or bind to cells. A
nanoviricide is believed to act like a decoy of a human cell. When
the virus sees the appropriate mimic of its cell binding site
displayed on a nanoviricide, the virus binds to it. The Company
believes that the flexible nanoviricide enables cooperative binding
of the nanoviricide to additional sites on the virus surface in a
velcro-like effect. This maximization of virus binding would lead
to the nanoviricide spreading onto the virus particle, fusing
with the virus surface, and then engulfing the virus. In the
process, the coat proteins that the virus uses for binding to cells
would be expected to become unavailable, and could fall off the
virus surface. This highly targeted attack would lead to the
loss of the viral coat proteins and the nanoviricide may further
dismantle the engulfed virus capsid. The loss of virus
particle integrity would neutralize the virus, making the virus
non-infectious.
The Handbook of Clinical Nanomedicine, Vol. 1.
Nanoparticles, Imaging, Therapy, and Clinical
Applications, edited by Raj Bawa, PhD, Gerald F. Audette,
PhD, and Israel Rubinstein, MD, is
the first volume in a two volume set published by CRC Press; it is
part of the Pan Stanford Series on Nanomedicine. The publisher
states that Volume 1 "provides a comprehensive roadmap of basic
research in nanomedicine as well as clinical applications. It
not only highlights current advances in diagnostics and therapies
but also explores related issues like nomenclature, terminology,
historical developments, and regulatory aspects. While bridging the
gap between basic biomedical research, engineering, medicine and
law, the handbook provides a thorough understanding of nano's
potential to address (i) medical problems from both the patient and
health provider's perspective, and (ii) current applications and
their potential in a healthcare setting." The CRC Press lists the
official publication date as February 28,
2016.
(https://www.crcpress.com/Handbook-of-Clinical-Nanomedicine-Two-Volume-Set/Bawa-Audette-Rubinstein/9789814316170).
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage
company that is creating special purpose nanomaterials for
antiviral therapy. The Company's novel nanoviricide® class of drug
candidates are designed to specifically attack enveloped virus
particles and to dismantle them. The Company is developing drugs
against a number of viral diseases including H1N1 swine flu, H5N1
bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral
diseases of the eye including EKC and herpes keratitis, Hepatitis
C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities.
Although it is not possible to predict or identify all such
factors, they may include the following: demonstration and proof of
principle in pre-clinical trials that a nanoviricide is safe and
effective; successful development of our product candidates; our
ability to seek and obtain regulatory approvals, including with
respect to the indications we are seeking; the successful
commercialization of our product candidates; and market acceptance
of our products.
Logo - http://photos.prnewswire.com/prnh/20150107/167444LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nanoviricides-anti-virus-technology-published-in-handbook-of-clinical-nanomedicine-300223569.html
SOURCE NanoViricides, Inc.